LV12755B - Pie c-21 modificetie epotiloni - Google Patents

Pie c-21 modificetie epotiloni

Info

Publication number
LV12755B
LV12755B LV010126A LV010126A LV12755B LV 12755 B LV12755 B LV 12755B LV 010126 A LV010126 A LV 010126A LV 010126 A LV010126 A LV 010126A LV 12755 B LV12755 B LV 12755B
Authority
LV
Latvia
Prior art keywords
modified epothilones
epothilones
modified
Prior art date
Application number
LV010126A
Other languages
English (en)
Latvian (lv)
Other versions
LV12755A (en
Inventor
Gerhard Hoefle
Nicole Glaser
Thomas Leibold
Gregory Vite
Soong-Hoon Kim
Original Assignee
Biotechnolog Forschung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Biotechnolog Forschung Gmbh filed Critical Biotechnolog Forschung Gmbh
Publication of LV12755A publication Critical patent/LV12755A/en
Publication of LV12755B publication Critical patent/LV12755B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
LV010126A 1999-02-22 2001-08-23 Pie c-21 modificetie epotiloni LV12755B (lv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (2)

Publication Number Publication Date
LV12755A LV12755A (en) 2001-11-20
LV12755B true LV12755B (lv) 2002-04-20

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
LV010126A LV12755B (lv) 1999-02-22 2001-08-23 Pie c-21 modificetie epotiloni

Country Status (37)

Country Link
US (1) US6262094B1 (ko)
EP (1) EP1157023B1 (ko)
JP (1) JP4598957B2 (ko)
KR (1) KR100685336B1 (ko)
CN (1) CN1205208C (ko)
AR (1) AR028815A1 (ko)
AT (1) ATE254615T1 (ko)
AU (1) AU771089B2 (ko)
BG (1) BG64987B1 (ko)
BR (1) BR0008379A (ko)
CA (1) CA2360452C (ko)
CO (1) CO5140093A1 (ko)
CZ (1) CZ301498B6 (ko)
DE (1) DE60006649T2 (ko)
DK (1) DK1157023T3 (ko)
EE (1) EE04852B1 (ko)
ES (1) ES2209831T3 (ko)
GE (1) GEP20033067B (ko)
HK (1) HK1038923B (ko)
HU (1) HUP0200076A3 (ko)
ID (1) ID29829A (ko)
IL (1) IL144501A0 (ko)
LT (1) LT4944B (ko)
LV (1) LV12755B (ko)
MX (1) MXPA01008374A (ko)
MY (1) MY120601A (ko)
NO (1) NO320806B1 (ko)
NZ (1) NZ513629A (ko)
PE (1) PE20001546A1 (ko)
PL (1) PL212545B1 (ko)
PT (1) PT1157023E (ko)
RU (1) RU2253652C2 (ko)
SK (1) SK287200B6 (ko)
TR (1) TR200102401T2 (ko)
TW (1) TWI270546B (ko)
UY (1) UY26024A1 (ko)
WO (1) WO2000050423A1 (ko)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU756699B2 (en) * 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
AU2001291876C1 (en) * 2000-09-22 2006-11-23 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) Triazolo-epothilones
CA2425828A1 (en) * 2000-10-13 2002-04-18 The University Of Mississippi Synthesis of epothilones and related analogs
CA2434566A1 (en) 2001-01-25 2002-08-15 Timothy M. Malloy Parenteral formulation containing epothilone analogs
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
RU2003128312A (ru) * 2001-02-20 2005-02-10 Бристол-Маерс Сквибб Компани (Us) Производные эпотилона, используемые для лечения резистентных опухлей
EP1385529A4 (en) 2001-02-20 2007-05-09 Bristol Myers Squibb Co TREATMENT OF REFRACTORY TUMORS USING EPOTHILONE DERIVATIVES
US7312237B2 (en) * 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
KR20040078123A (ko) * 2002-01-14 2004-09-08 노파르티스 아게 에포틸론 및 대사길항물질을 포함하는 조합물
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003212457A1 (en) * 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
EP1854464A3 (en) * 2002-03-08 2008-06-04 Novartis AG Combinations comprising epothilone derivatives and alkylating agents
CN100402029C (zh) * 2002-03-08 2008-07-16 诺瓦提斯公司 包含埃坡霉素衍生物和烷化剂的组合
DE60330651D1 (en) 2002-03-12 2010-02-04 Bristol Myers Squibb Co C3-cyanoepothilonderivate
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
BR0309711A (pt) * 2002-05-01 2005-02-09 Novartis Ag Método para o tratamento de doenças do câncer
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003260002B2 (en) 2002-08-23 2010-03-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
GEP20074017B (en) 2002-09-23 2007-01-10 Bristol Myers Squibb Co Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
EP1551378A4 (en) * 2002-10-09 2006-09-06 Kosan Biosciences Inc EPO D + 5-FU / GEMCITABIN
WO2004071440A2 (en) 2003-02-06 2004-08-26 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1958625A1 (en) * 2004-11-18 2008-08-20 Brystol-Myers Squibb Company Enteric coate bead comprising ixabepilone and preparation thereof
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
WO2007062288A2 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
US20100099090A1 (en) * 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
CN101754969A (zh) 2007-05-25 2010-06-23 百时美施贵宝公司 制备埃坡霉素化合物和类似物的方法
CN101909693A (zh) 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
CN104666297A (zh) * 2008-04-24 2015-06-03 百时美施贵宝公司 埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
EP2286220A2 (en) * 2008-05-29 2011-02-23 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
US8119129B2 (en) * 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
EP2947098B1 (en) 2009-07-20 2019-11-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with gemcitabine for the synergistic treatment of proliferative diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
MY168757A (en) 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP3227335A1 (en) 2014-12-04 2017-10-11 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
PT3313528T (pt) 2015-06-29 2021-09-16 Bristol Myers Squibb Co Regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do cancro
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (ko)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
ES2218328T5 (es) 1995-11-17 2011-11-11 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Derivados de epotilón, su preparación y utilización.
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
CA2281105A1 (en) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
US6348551B1 (en) 1997-04-18 2002-02-19 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
EP1001951B1 (de) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
CA2356360A1 (en) * 1998-12-23 2000-07-06 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone

Also Published As

Publication number Publication date
AU771089B2 (en) 2004-03-11
DK1157023T3 (da) 2004-03-29
ES2209831T3 (es) 2004-07-01
CZ301498B6 (cs) 2010-03-24
CA2360452C (en) 2011-07-26
PL212545B1 (pl) 2012-10-31
JP2002537395A (ja) 2002-11-05
US6262094B1 (en) 2001-07-17
EP1157023B1 (en) 2003-11-19
BR0008379A (pt) 2002-09-24
LT2001086A (en) 2002-04-25
AU3234800A (en) 2000-09-14
IL144501A0 (en) 2002-05-23
HK1038923A1 (en) 2002-04-04
MY120601A (en) 2005-11-30
EE04852B1 (et) 2007-06-15
HUP0200076A3 (en) 2003-01-28
NZ513629A (en) 2004-01-30
SK10782001A3 (sk) 2002-03-05
JP4598957B2 (ja) 2010-12-15
EP1157023A1 (en) 2001-11-28
CA2360452A1 (en) 2000-08-31
PT1157023E (pt) 2004-03-31
TR200102401T2 (tr) 2001-12-21
LT4944B (lt) 2002-08-26
WO2000050423A1 (en) 2000-08-31
ATE254615T1 (de) 2003-12-15
CN1205208C (zh) 2005-06-08
EE200100437A (et) 2002-12-16
CN1341114A (zh) 2002-03-20
NO320806B1 (no) 2006-01-30
SK287200B6 (sk) 2010-03-08
TWI270546B (en) 2007-01-11
KR100685336B1 (ko) 2007-02-23
LV12755A (en) 2001-11-20
AR028815A1 (es) 2003-05-28
GEP20033067B (en) 2003-09-25
MXPA01008374A (es) 2003-06-06
UY26024A1 (es) 2000-09-29
ID29829A (id) 2001-10-11
DE60006649D1 (de) 2003-12-24
NO20014017L (no) 2001-10-17
HUP0200076A2 (hu) 2002-12-28
HK1038923B (zh) 2004-03-19
CO5140093A1 (es) 2002-03-22
BG64987B1 (bg) 2006-11-30
DE60006649T2 (de) 2004-09-30
NO20014017D0 (no) 2001-08-17
BG105830A (en) 2002-03-29
PL350179A1 (en) 2002-11-18
RU2253652C2 (ru) 2005-06-10
KR20010102199A (ko) 2001-11-15
PE20001546A1 (es) 2001-03-18
CZ20012991A3 (cs) 2002-01-16

Similar Documents

Publication Publication Date Title
LV12755B (lv) Pie c-21 modificetie epotiloni
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077D0 (no) Amino-triazolopyridin-derivater
ATE263748T1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
NO20021803L (no) Isoksazolkarboksamid-derivater
ATE257148T1 (de) Propargyletherderivate
ATE273272T1 (de) Mevinolinderivate
ATE374747T1 (de) Monofluoralkylderivate
DK1218340T3 (da) 4-hydroxybiphenylhydrazid-derivater
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
ATE293592T1 (de) Resorcinderivate
DE60004451D1 (de) Isothiazolonkonzentrate
NO20022867D0 (no) Syklopentenon-derivater
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DK1189886T3 (da) Ethansulfonyl-piperidinderivater
DK1178984T3 (da) 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
SE9902631D0 (sv) Återförslutbart burklock
FI3963U1 (fi) Tii
SE9904417D0 (sv) Crystalline form
ATE288902T1 (de) Oxazolidinon-derivate